Dec 21, 2025
Lenacapavir, approved in June, is a twice-yearly injectable.
seen from United States
seen from Malaysia
seen from Sweden
seen from United States
seen from United States
seen from China
seen from United States
seen from Malaysia
seen from China
seen from United States
seen from United States
seen from Saudi Arabia
seen from United States
seen from United States
seen from Malaysia
seen from United States
seen from United States
seen from Belgium
seen from United States
seen from United States
Lenacapavir, approved in June, is a twice-yearly injectable.
The new rule was contained within a larger proposal to ensure contraceptive coverage in the face of Republican attacks.
A study involving macaques showed the injectable implant as fully effective at preventing HIV.
Since 2017, a joint study between the Centers for Disease Control Prevention and the University of North Carolina has worked to develop an injectable implant that can release pre-exposure prophylaxis (PrEP) medications into the body for an extended period of time. The latest research, published in Nature Communications, shows that the most recent formulation can provide up to six months of full protection against HIV in non-human primates. “This is the first time we showed 100% protection against multiple virus challenges in a macaque model of PrEP over an extended period of time,” said Rahima Benhabbour, PhD, MSc, associate professor at the UNC/NCSU Joint Department of Biomedical Engineering in a statement. “Our goal with this technology is a once or twice-yearly injection that could be self-administered.” Benhabbour and team have focused on refining the material contained in the injection, using cabotegravir, which is currently available as an injection every two months, as the main focus.
continue reading